GO:0071357 cellular response to type I interferon: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0071357 describes the cellular response to type I interferons (IFN-alpha, IFN-beta, and related cytokines), a central innate immune signaling process.
• Type I interferon signaling is initiated by JAK-STAT pathways and drives expression of hundreds of interferon-stimulated genes (ISGs) that restrict viral replication and modulate immunity.
• The cGAS-STING axis is a major upstream sensor pathway that triggers type I interferon production in response to cytosolic DNA.
• Type I interferon responses are spatially organized in tissues, with clustered responses at injury border zones and in microglia during cortical development.
• Dysregulated type I interferon signaling contributes to autoimmunity, tuberculosis susceptibility, and neurotoxicity, making it a key therapeutic target.
• CRISPR knockout, knock-in, and overexpression models enable causal dissection of ISGs and interferon pathway components in disease contexts.
Description
The cellular response to type I interferon (GO:0071357) is a fundamental biological process through which cells sense and react to type I interferons, including IFN-alpha, IFN-beta, IFN-delta, IFN-epsilon, IFN-zeta, IFN-kappa, IFN-tau, and IFN-omega. This response is critical for antiviral defense, immune regulation, and tissue homeostasis, and it is initiated when type I interferons bind to the IFNAR receptor complex, activating JAK-STAT signaling and inducing a broad transcriptional program of interferon-stimulated genes (ISGs). The importance of this process is underscored by its evolutionary conservation and its involvement in diverse physiological and pathological states, from host defense against pathogens to autoimmune diseases and neurodevelopmental processes. Researchers study GO:0071357 to understand how cells coordinate innate immunity, how pathogens evade interferon responses, and how dysregulation leads to disease. The cGAS-STING pathway is a key upstream activator of type I interferon production in response to cytosolic DNA, linking DNA sensing to interferon-driven immunity. Recent work has revealed that type I interferon responses are not uniform but spatially clustered in tissues, such as at injury border zones and in microglia during cortical development, highlighting the importance of cellular context. Moreover, type I interferon signaling can be modulated by metabolic cues, such as spermine, which targets JAK signaling to restrain autoimmunity. Given its broad impact, GO:0071357 is a focal point for biomedical research, with implications for infectious diseases, cancer, autoimmunity, and neurobiology. Understanding the molecular players and regulatory mechanisms of this response is essential for developing targeted therapies and for interpreting genome-wide screens and CRISPR-based models.
cellular response to type I interferon At A Glance
| GO ID | GO:0071357 |
|---|---|
| GO term | cellular response to type I interferon |
| Ontology | biological_process |
| Synonym | cellular response to type I IFN |
| Definition | Any process that results in a change in state or activity of a cell as a result of a type I interferon stimulus. |
| Major function | Mediates cellular responses to type I interferons, including antiviral defense, immune modulation, and gene expression reprogramming. |
| Upstream activators | cGAS-STING pathway, cytosolic DNA sensing, and other pattern recognition receptors. |
| Key signaling mediators | JAK kinases, STAT transcription factors, and interferon regulatory factors. |
| Representative ISGs | ISG15, MX1, OAS1, IFIT1, and many others with antiviral effector functions. |
What Is GO:0071357?
GO:0071357, cellular response to type I interferon, is defined as any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a type I interferon stimulus. Type I interferons include the interferon-alpha, beta, delta, epsilon, zeta, kappa, tau, and omega gene families. This term encompasses the signaling cascades, transcriptional changes, and functional outcomes that occur when a cell encounters type I interferon, such as activation of JAK-STAT pathways and induction of interferon-stimulated genes.
Why Is cellular response to type I interferon Important in Cell Biology?
GO:0071357 is critically important because type I interferon signaling is a first line of defense against viral infections and a key regulator of immune responses, and its dysregulation is linked to a wide range of human diseases, including autoimmune disorders, tuberculosis susceptibility, and neurodevelopmental abnormalities. Understanding this process at the cellular level provides insights into host-pathogen interactions, immune homeostasis, and potential therapeutic targets for modulating interferon responses in disease.
• Antiviral immunity: type I interferon responses restrict replication of diverse viruses through ISG effectors.
• Autoimmunity: excessive or prolonged type I interferon signaling contributes to autoimmune diseases such as lupus and is restrained by metabolic checkpoints like spermine.
• Tuberculosis susceptibility: early type I interferon-driven mechanisms increase susceptibility to Mycobacterium tuberculosis.
• Neurodevelopment: type I interferon-responsive microglia shape cortical development and behavior.
• Tissue repair: spatially clustered type I interferon responses occur at injury border zones, influencing regeneration.
• Neurotoxicity: type I interferon neurotoxicity in the brain is associated with neurological disorders.
• Cancer immunology: type I interferons enhance antigen presentation and immune surveillance, and are used in cancer immunotherapy.
• Drug discovery: targeting JAK-STAT or cGAS-STING components can modulate interferon responses for therapeutic benefit.
• CRISPR screening: genome-wide knockout screens have identified numerous ISG effectors and regulators of type I interferon response.
• Biomarker development: interferon-stimulated gene signatures are used as biomarkers in autoimmune and infectious diseases.
What Happens During cellular response to type I interferon?
Recognition of type I interferon and receptor activation
In simple terms: The cell detects interferon outside and gets ready to respond.
Type I interferons bind to the heterodimeric IFNAR1/IFNAR2 receptor on the cell surface, triggering conformational changes that activate associated JAK kinases (JAK1 and TYK2). This activation leads to phosphorylation of STAT1 and STAT2, which form a complex with IRF9 (ISGF3) that translocates to the nucleus to initiate transcription of interferon-stimulated genes (ISGs). This canonical JAK-STAT pathway is the central signaling module of GO:0071357.
Transcriptional reprogramming and ISG expression
In simple terms: The cell turns on hundreds of antiviral genes.
Activated STAT complexes drive expression of hundreds of ISGs, including antiviral effectors such as MX1, OAS1, IFIT1, and ISG15, which collectively establish an antiviral state and modulate immune signaling. The specific repertoire of ISGs induced depends on cell type, context, and additional transcription factors, and genome-wide studies have identified a diverse range of gene products as effectors of the type I interferon antiviral response.
Amplification and crosstalk with DNA-sensing pathways
In simple terms: Other sensors can boost the interferon response.
The cGAS-STING pathway senses cytosolic DNA and activates TBK1-IRF3 signaling to induce type I interferon production, which then acts in an autocrine and paracrine manner to amplify cellular responses through GO:0071357. STING is essential for intracellular DNA-mediated, type I interferon-dependent innate immunity, and its activation is tightly regulated to avoid autoimmunity. This crosstalk integrates DNA damage, infection, and cellular stress into the interferon response.
Spatial and contextual organization of the response
In simple terms: Interferon responses happen in specific places in tissues.
Type I interferon responses are not uniformly distributed; they can be spatially clustered at injury border zones and in specific cell types such as microglia during cortical development. These spatial patterns influence tissue repair, neural development, and behavior, demonstrating that GO:0071357 operates within complex tissue microenvironments.
Metabolic and regulatory checkpoints
In simple terms: Metabolites can put brakes on interferon signaling.
Cellular metabolites such as spermine can directly target JAK signaling to restrain cytokine-mediated autoimmunity, providing a layer of metabolic control over type I interferon responses. This regulation prevents excessive inflammation and highlights potential therapeutic entry points for modulating GO:0071357 in autoimmune diseases.
Key Genes Involved in GO:0071357 cellular response to type I interferon
The following genes and proteins are central to the cellular response to type I interferon (GO:0071357), based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IFNAR1 | Type I interferon receptor subunit 1; binds interferons and activates JAK-STAT signaling | Knockout models abolish type I interferon response; target for blocking interferon signaling |
| IFNAR2 | Type I interferon receptor subunit 2; essential for high-affinity ligand binding and signaling | Mutations affect interferon responsiveness; used in receptor structure-function studies |
| JAK1 | Janus kinase 1; phosphorylates STAT proteins downstream of IFNAR | Kinase inhibitor target; knockout reduces ISG induction |
| TYK2 | Tyrosine kinase 2; partners with JAK1 to activate STATs | Deficiency impairs antiviral immunity; drug target for autoimmune diseases |
| STAT1 | Signal transducer and activator of transcription 1; forms ISGF3 complex | Loss-of-function causes Mendelian susceptibility to mycobacterial diseases; key readout of pathway activation |
| STAT2 | Signal transducer and activator of transcription 2; part of ISGF3 | Essential for ISG transcription; knockout used to dissect interferon-specific responses |
| IRF9 | Interferon regulatory factor 9; DNA-binding subunit of ISGF3 | Required for ISG induction; studied in antiviral and autoimmune models |
| STING1 | Stimulator of interferon genes; senses cytosolic DNA and activates IRF3 | Knockout abolishes DNA-mediated type I interferon production; linked to autoinflammatory diseases |
| CGAS | Cyclic GMP-AMP synthase; produces cGAMP to activate STING | Target for cancer immunotherapy and autoimmune disease research |
| IRF3 | Interferon regulatory factor 3; transcription factor activated by TBK1 | Phosphorylation and nuclear translocation are key markers of pathway activation |
| ISG15 | Ubiquitin-like protein induced by interferon; modulates antiviral immunity | Knockout mice show increased viral susceptibility; biomarker of interferon response |
| MX1 | Myxovirus resistance 1; GTPase with antiviral activity | Classic ISG effector; used as a readout of type I interferon signaling |
| OAS1 | 2'-5'-oligoadenylate synthetase 1; activates RNase L to degrade viral RNA | Polymorphisms linked to viral susceptibility; effector of interferon response |
| IFIT1 | Interferon-induced protein with tetratricopeptide repeats 1; inhibits viral translation | Knockout enhances viral replication; marker of ISG induction |
| SOCS1 | Suppressor of cytokine signaling 1; negative regulator of JAK-STAT | Overexpression dampens interferon responses; knockout causes autoimmunity |
| USP18 | Ubiquitin-specific protease 18; negative regulator of type I interferon signaling | Knockout leads to enhanced interferon response and neurotoxicity |
| PTPN2 | Protein tyrosine phosphatase non-receptor type 2; attenuates JAK-STAT signaling | Risk gene for autoimmune diseases; modulates interferon sensitivity |
| SPM/ODC1 | Spermine biosynthesis pathway; spermine targets JAK signaling | Metabolic checkpoint of interferon responses; knockout alters autoimmunity |
How Is cellular response to type I interferon Regulated?
The cellular response to type I interferon is tightly regulated at multiple levels. Negative regulators such as SOCS1, USP18, and PTPN2 attenuate JAK-STAT signaling to prevent excessive inflammation and autoimmunity. Metabolic cues, including spermine, can directly inhibit JAK signaling, providing a link between cellular metabolism and interferon responsiveness. Additionally, the cGAS-STING pathway is subject to regulation by post-translational modifications and trafficking to avoid aberrant activation. Spatial organization and cell-type-specific factors further shape the intensity and duration of the response in tissues.
cellular response to type I interferon and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| STAT1 | Mendelian susceptibility to mycobacterial diseases; impaired interferon signaling | Knockout and point-mutation knock-in in macrophages |
| STING1 | Autoinflammatory diseases (SAVI); aberrant type I interferon production | Knock-in of gain-of-function mutations in mice |
| USP18 | Interferonopathies; enhanced type I interferon neurotoxicity | Knockout mice and neural cell models |
| SOCS1 | Autoimmunity; loss of negative regulation of JAK-STAT | Knockout and overexpression in T cells |
| IFNAR1 | Viral susceptibility; abolished type I interferon response | Knockout cell lines and mice |
Type I interferon in tuberculosis susceptibility
Early cellular mechanisms of type I interferon-driven susceptibility to tuberculosis involve the induction of permissive myeloid cell states that favor Mycobacterium tuberculosis growth. This highlights GO:0071357 as a determinant of host-pathogen outcomes and a potential target for host-directed therapies.
Type I interferon and neurodevelopmental disorders
Type I interferon-responsive microglia shape cortical development and behavior, and dysregulation of this response can lead to neurodevelopmental abnormalities. Additionally, type I interferon neurotoxicity in the brain is associated with neurological dysfunction, underscoring the need to understand cell-type-specific responses.
Autoimmunity and metabolic control
Cellular spermine targets JAK signaling to restrain cytokine-mediated autoimmunity, demonstrating that metabolic checkpoints can prevent excessive type I interferon responses. Defects in negative regulators such as USP18 or SOCS1 are linked to interferonopathies and autoimmune conditions.
Tissue injury and repair
Spatially clustered type I interferon responses at injury border zones influence tissue repair processes, and their dysregulation may contribute to chronic inflammation or impaired regeneration. Understanding these spatial dynamics is important for developing therapies that modulate interferon responses in injured tissues.
From cellular response to type I interferon-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a candidate ISG restrict viral replication? | CRISPR knockout in permissive cell lines followed by viral infection |
| How do point mutations in STING affect interferon signaling? | Knock-in of patient-derived mutations in cell lines or mice |
| Can a gene fusion report ISG induction? | Knock-in of fluorescent reporter at an ISG locus |
| What is the effect of overexpressing a negative regulator? | Doxycycline-inducible overexpression in macrophages |
| Which genes are essential for type I interferon response? | Genome-wide CRISPR knockout library screening |
| How does spatial organization affect interferon response? | Tissue-specific knockout or reporter mice |
How to Study the cellular response to type I interferon Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global changes in gene expression | Identifying ISGs induced by type I interferon |
| qPCR | Expression of specific ISGs | Validating knockout or overexpression effects |
| Western blot | Protein levels and phosphorylation of JAK-STAT | Assessing pathway activation |
| Immunofluorescence | Spatial distribution of interferon-responsive cells | Tissue-level analysis of response clustering |
| CRISPR knockout screening | Essential genes for interferon response | Discovery of novel pathway components |
| Mass spectrometry | Protein abundance and modifications | Phosphoproteomic analysis of signaling |
| Flow cytometry | Single-cell STAT phosphorylation | Quantifying response heterogeneity |
| In situ hybridization | Localization of ISG mRNA | Visualizing tissue-specific responses |
Transcriptomic profiling of ISG induction
RNA-seq and qPCR are used to measure the induction of interferon-stimulated genes following type I interferon treatment, providing a global view of transcriptional reprogramming in GO:0071357. These methods are essential for validating CRISPR knockouts and for identifying novel ISGs.
Proteomic and phosphoproteomic analysis
Mass spectrometry-based proteomics can quantify changes in protein abundance and phosphorylation of JAK-STAT components after interferon stimulation, revealing signaling dynamics and feedback regulation. This approach helps identify post-translational modifications that control the response.
Imaging of spatial interferon responses
Immunofluorescence and in situ hybridization can visualize the spatial clustering of type I interferon responses at tissue border zones and in specific cell types such as microglia. These techniques are critical for understanding tissue-level organization of GO:0071357.
CRISPR screening for pathway regulators
Genome-wide CRISPR knockout screens have been used to identify effectors and regulators of the type I interferon antiviral response, uncovering a diverse range of gene products. Such screens are powerful for discovering novel components of GO:0071357.
How CRISPR Can Be Used to Study GO:0071357 cellular response to type I interferon
Knockout
CRISPR knockout of genes such as IFNAR1, STAT1, or STING1 abolishes or reduces type I interferon responses, enabling researchers to test causality in antiviral immunity and autoimmunity models. Knockout cell lines are also used in genome-wide screens to identify ISG effectors.
Point Mutation
Point mutations in genes like STING1 or STAT1 can be introduced to model patient-derived variants and dissect signaling mechanisms, such as gain-of-function mutations causing autoinflammatory diseases. These models help link specific amino acid changes to altered interferon responses.
Knock-in
Knock-in of reporter genes (e.g., fluorescent proteins) at ISG loci allows real-time monitoring of type I interferon response activation in live cells and tissues. Knock-in of tagged alleles also facilitates biochemical studies of pathway components.
Overexpression
Overexpression of negative regulators such as SOCS1 or USP18 can suppress type I interferon signaling, while overexpression of ISGs can enhance antiviral activity, providing gain-of-function insights into GO:0071357. Inducible overexpression systems allow temporal control of pathway modulation.
How EDITGENE Supports cellular response to type I interferon Research
Researchers studying cellular response to type I interferon-related genes often need to determine whether a candidate gene is causally involved in interferon signaling, whether specific mutations alter pathway activity, or whether overexpression or knockout can modulate disease phenotypes. EDITGENE provides comprehensive CRISPR-based services to address these questions with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for cellular response to type I interferon research.
Frequently Asked Questions About cellular response to type I interferon
What is GO:0071357 cellular response to type I interferon?
GO:0071357 is a Gene Ontology biological process term describing any cellular change triggered by type I interferons, including JAK-STAT signaling and ISG induction.
What genes are involved in cellular response to type I interferon?
Key genes include IFNAR1, IFNAR2, JAK1, TYK2, STAT1, STAT2, IRF9, STING1, CGAS, and numerous ISGs such as ISG15, MX1, and OAS1.
How does type I interferon signaling work?
Type I interferons bind IFNAR receptors, activating JAK kinases that phosphorylate STAT1/STAT2, which with IRF9 form ISGF3 to induce ISGs.
What diseases are linked to type I interferon responses?
Dysregulated type I interferon signaling is linked to autoimmunity, tuberculosis susceptibility, neurodevelopmental disorders, and interferonopathies.
What is the role of STING in type I interferon response?
STING senses cytosolic DNA and activates IRF3 to induce type I interferon production, bridging DNA sensing to GO:0071357.
How can I study cellular response to type I interferon using CRISPR?
CRISPR knockout, knock-in, point mutation, and overexpression models allow causal testing of genes in the type I interferon pathway.
What are interferon-stimulated genes (ISGs)?
ISGs are genes whose expression is induced by type I interferon signaling, encoding antiviral effectors and immune modulators.
Is type I interferon response involved in neurodevelopment?
Yes, type I interferon-responsive microglia shape cortical development and behavior, and neurotoxicity is linked to neurological disorders.
What is the cGAS-STING pathway?
The cGAS-STING pathway detects cytosolic DNA and triggers type I interferon production through TBK1-IRF3 signaling.
How is type I interferon signaling regulated?
It is regulated by negative feedback via SOCS1, USP18, PTPN2, and metabolic cues such as spermine that target JAK signaling.
Conclusion
GO:0071357 cellular response to type I interferon is a cornerstone of innate immunity and cellular homeostasis, with far-reaching implications for infectious diseases, autoimmunity, neurodevelopment, and cancer. The integration of JAK-STAT signaling, cGAS-STING sensing, and spatial organization underscores the complexity of this process and the need for precise experimental models. CRISPR-based approaches, including knockout, knock-in, point mutation, and overexpression, provide powerful tools to dissect the molecular players and regulatory mechanisms of type I interferon responses. Continued research into GO:0071357 will advance our understanding of host-pathogen interactions and guide the development of targeted therapies for interferon-related diseases.
References
- 1. Kotov DI et al.. 2023. Early cellular mechanisms of type I interferon-driven susceptibility to tuberculosis.. Cell 186(25):5536-5553.e22 PMID: 38029747
- 2. Escoubas CC et al.. 2024. Type-I-interferon-responsive microglia shape cortical development and behavior.. Cell 187(8):1936-1954.e24 PMID: 38490196
- 3. Schoggins JW et al.. 2011. A diverse range of gene products are effectors of the type I interferon antiviral response.. Nature 472(7344):481-5 PMID: 21478870
- 4. Hopfner KP et al.. 2020. Molecular mechanisms and cellular functions of cGAS-STING signalling.. Nat Rev Mol Cell Biol 21(9):501-521 PMID: 32424334
- 5. Ninh VK et al.. 2024. Spatially clustered type I interferon responses at injury borderzones.. Nature 633(8028):174-181 PMID: 39198639
- 6. Xu H et al.. 2024. Cellular spermine targets JAK signaling to restrain cytokine-mediated autoimmunity.. Immunity 57(8):1796-1811.e8 PMID: 38908373
- 7. Viengkhou B et al.. 2023. Breaking down the cellular responses to type I interferon neurotoxicity in the brain.. Front Immunol 14:1110593 PMID: 36817430
- 8. Ishikawa H et al.. 2009. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity.. Nature 461(7265):788-92 PMID: 19776740
